England's NICE backs Merck & Co's Ezetrol for primary hypercholesterolemia
Medicines watchdog for England and Wales the National Institute for Health and Care Excellence (NICE) has today published draft guidance recommending US pharma giant Merck & Co’s (NYSE: MRK) Ezetrol (ezetimibe) as an option for some adults with primary (heterozygous-familial and non-familial) hypercholesterolemia. The draft guidance updates NICE’s previous guidance on the use of these drugs.
The draft guidance provisionally recommends ezetimibe on its own for adults with primary heterozygous-familial and non-familial hypercholesterolemia when a statin is considered inappropriate or is not tolerated, only if:
- they need lipid modification therapy for the primary prevention of cardiovascular disease and have both: - type 2 diabetes and
- a 20% or greater 10 year risk of developing cardiovascular disease according to the QRISK2 risk assessment tool, or
• they need lipid-modification therapy for the secondary prevention of cardiovascular disease.
“Primary hypercholesterolemia is an important risk factor for developing cardiovascular disease (CVD), the most common cause of death in the UK, as well as being a major cause of morbidity and reduced quality of life. This draft guidance is therefore good news some people with this condition who aren’t able to take a statin to reduce their cholesterol,” commented Carole Longson, director of the NICE Centre for Health Technology Evaluation.
Today’s draft guidance is different to the original 2007 guidance because it reflects the fact that current clinical practice has a greater emphasis on managing CVD risk rather than meeting target cholesterol levels, the NICE pointed out.
ICERs and QALY
The NICE Appraisal Committee concluded that in the primary prevention population of CVD the most plausible incremental cost-effectiveness ratios (ICERs) were as follows:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze